Can healthcare go from good to great?

J Hosp Med

School of Medicine, University of California, San Francisco, San Francisco, California.

Published: January 2012

Healthcare's improvement efforts have focused on the point of care, targeting specific processes such as preventing central line infections, while paying relatively less attention to the larger issues of organizational structure and leadership. Interestingly, the business community has long recognized that poor management and structure can thwart improvement efforts. Perhaps the corporate world's best-known study of these issues is found in the book Good to Great, which identifies top-performing corporations, compares them to carefully selected organizations that failed to achieve similar levels of performance, and gleans lessons from these analyses. In this article, we analyze the feasibility of carefully applying Good to Great's methods for analyzing organizational structure and leadership to healthcare. While a few studies in healthcare have come close to emulating Good to Great's methodology, none have matched its rigor. These shortcomings highlight key information and measurement gaps that must be addressed to facilitate unbiased, rigorous studies of the organizational and leadership predictors of institutional excellence in healthcare.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jhm.957DOI Listing

Publication Analysis

Top Keywords

improvement efforts
8
organizational structure
8
structure leadership
8
good great's
8
healthcare
4
healthcare good
4
good great?
4
great? healthcare's
4
healthcare's improvement
4
efforts focused
4

Similar Publications

A study on how to improve students' continuance intention in landscape architecture conservation course within a virtual learning environment based on SVVR.

Acta Psychol (Amst)

January 2025

Department of Culture and Arts Management, Honam University, 62399 Gwangju, South Korea. Electronic address:

With the rapid pace of global urbanization, preserving natural landscapes has become increasingly critical. However, urbanization presents significant environmental risks worsened by decreased ecological consciousness. This has led to a pressing demand for education in landscape conservation.

View Article and Find Full Text PDF

Allodynia (skin tenderness) associated with semaglutide: A case series.

Am J Health Syst Pharm

January 2025

Veterans Health Care System of the Ozarks, Fayetteville, AR, USA.

Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

View Article and Find Full Text PDF

Medical devices significantly enhance healthcare by integrating advanced technology to improve patient outcomes. Ensuring their safety and reliability requires a delicate balance between innovation and rigorous oversight, managed through the collaborative efforts of standards development organizations, standards accrediting organizations, and regulatory agencies such as the U.S.

View Article and Find Full Text PDF

From Vision to Reality: The EU's Pharmaceutical Reforms and the Path to Improved Access.

Pharmacoecon Open

January 2025

Department of Health Policy and Medical Technology Research Group, LSE Health, London School of Economics and Political Science, London, UK.

Disparities in access to oncology medicines in European Union (EU) member states can impact patient outcomes profoundly, with availability and timely access varying significantly across and within member states. This paper discusses the intersection of the new European Health Technology Assessment Regulation (HTAR), the provisions of the proposed pharmaceutical legislation and their potential impacts on access to oncology medicines across EU member states. The HTAR, seeking to standardise the clinical evaluation of new medicines, has the potential to streamline the evaluation process but also risks oversimplifying diverse national healthcare needs.

View Article and Find Full Text PDF

Biological therapy in Chronic rhinosinusitis with nasal polyps.

Expert Rev Clin Immunol

January 2025

Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.

Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease. High proportions of patients with CRSwNP characterized by type 2 inflammation fail to gain adequate control with conventional medical and surgical approaches. The application of biologics in clinical practice and assessments of novel biologics in clinical trials are blooming in expectations to fulfill the unmet medical needs of patients with CRSwNP with type 2 inflammation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!